Celldex Therapeutics Inc.
CLDX
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.35B
Close$
$0.04
99.9% downside
Current Fair Value
99.9% downsideOvervalued by 99.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.35 Billion |
|---|---|
| Enterprise Value | $2.32 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.9 |
| Beta | 0.9 |
| Outstanding Shares | 66,566,000 |
Return
| Return on Equity | -62.18% |
|---|---|
| Return on Assets | -55.49% |
| Return on Invested Capital | -46.17% |
Valuation & Multiples
| P/E Ratio | -8.28 |
|---|---|
| PEG | -17.89 |
| Price to Sales | - |
| Price to Book Ratio | 5.9 |
| Enterprise Value to Revenue | 2827.21 |
| Enterprise Value to EBIT | -10.92 |
| Enterprise Value to Net Income | -9 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-1.13
Average shareholder expectationRevenue Estimate
$795,364
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-1.04
Average shareholder expectationRevenue Estimate
$735,750
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 192.62% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.82%▼ 107.87% |
|---|---|
| Total Invested | $44.81M▼ 98.06% |
| Investors Holding | 19▼ 215.00% |
ESG Score
No data
About Celldex Therapeutics Inc.
CEO: Anthony Marucci Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeu...